Documentation Pharmaceutical Companies Webinar 
pharmaphorum
NOVEMBER 17, 2020
Pharmaceutical companies often struggle to actively involve patients in the design phase of clinical trials but doing so can have huge benefits for the sustainability and success of research. The webinar will also cover: Building better relationships between pharma/CROs and patient advocates.
Pharma Marketing Network
MARCH 18, 2025
Brand Authority: By appearing at the top of search engine results, pharmaceutical companies increase brand credibility among HCPs. Conversion Rate: Tracks how many users complete a desired action, such as signing up for a webinar or downloading whitepapers. Offer incentives like exclusive research reports or webinar invites.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Marketing Network
APRIL 16, 2025
Thats the promise of data-driven marketing , a strategy thats rapidly transforming how pharmaceutical companies approach promotion, education, and engagement in 2025. Imagine launching a brand campaign without guessworkwhere your message reaches the right healthcare professional at the right time on the right channel.
pharmaphorum
OCTOBER 27, 2022
The Guidance applies to all member companies of EFPIA and IFPMA, but also acts as useful guidance for all pharmaceutical companies as to how the authorities will interpret the legislative provisions to social media channels. The Guidance applies to both product-related and therapeutic-area-related activities.
Eye on FDA
JULY 7, 2020
The interesting thing in connection with that is that in May – in the midst of the COVID-19 pandemic – FDA held a Webinar on the “ Bad Ad” Program – a program that deputizes healthcare professionals to assess promotional communications and report potential violations to the agency.
Pharmaceutical Technology
DECEMBER 15, 2022
In addition, several pieces of documentation will be required to support the API qualification, e.g. pharmacopeial compliance. It is also essential to evaluate the reliability of the company supplying the ingredient: do they provide sufficient communication and documentation? Is Benzalkonium Chloride a good choice?
FDA Law Blog: Biosimilars
MAY 26, 2025
Hull & JP Ellison At our webinar earlier this month, we talked about Administration priorities as they relate to the FDC Act and noted that we expect much to remain the same with respect to enforcement. The gray box at the top of the document at this link shows the change in position. By Andrew J.
Expert insights. Personalized for you.
116 
Let's personalize your content